COMP <GO>
LUNG vs APYX // ALTMAN Z-SCORE & DEBT/EQUITY
Pulmonx Corporation (NASDAQ) VS. Apyx Medical Corporation (NASDAQ) • 15-METRIC TALLY: LUNG 4
— APYX 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: APYX
LAST: $3.01 (-5.05%) • MKT CAP: $135.9M
balance-sheet
0.20
LAST: $2.60 (-3.35%) • MKT CAP: $113.3M
balance-sheet
0.75
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LUNG VS. APYX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LUNG | APYX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.20% | 62.50% | +11.70 | LUNG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -28.90% | -6.10 | APYX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -24.15% | -8.04% | -16.11 | APYX | /fcf-yield <GO> |
| Operating Margin | -59.30% | -12.20% | -47.10 | APYX | /operating-margins <GO> |
| Net Profit Margin | -59.70% | -21.20% | -38.50 | APYX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 9.90% | -1.90 | APYX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.20 | 0.75 | -0.55 | APYX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | LUNG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 79.1 | 49.1 | +29.95 | LUNG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $135.9M | $113.3M | $22.6M | LUNG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LUNG REV | APYX REV | LUNG GROSS % | APYX GROSS % | LUNG FCF | APYX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $90.5M | $52.8M | 74.2% | 62.5% | -$32.8M | -$9.1M |
| FY 2024 | $83.8M | $48.1M | 74.0% | 61.0% | -$33.0M | -$18.8M |
| FY 2023 | $68.7M | $52.3M | — | — | -$37.6M | -$5.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LUNG // BETA —
APYX // BETA —